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SPONTANEOUS AND INDUCED
GENETIC MUTATIONS OF THE POMC
SYSTEM

James L. Smart and Malcolm J. Low

Vollum Institute, Oregon Health Sciences University, Portland OR 97201, U.S.A.

INTRODUCTION
Two

decades

ago

a

senes

of

biochemical

experiments

conclusively

demonstrated that adrenocorticotropin (ACTH) and f3-lipotropin (f3LPH)
peptides were stoichiometrically generated from a common precursor

(1).

This result was heralded by one of the landmark studies in the nascent field
of eukaryotic cloning, the sequencing of a pituitary eDNA whose deduced
amino acids encoded both peptides separated by a pair of basic amino acids
(Lys-Arg) (2).
(POMC)

Subsequent work demonstrated that the proopiomelanocortin

prohormone

is

posttranslationally

processed

biologically active peptides in addition to ACTH and f3LPH.

into

several

Among these

are the melanocortin melanocyte-stimulating hormone ( aMSH) and the
potent opioid f3-endorphin (f3END).

The mechanism of POMC processing

became a paradigm in cellular biology for the elucidation of vesicular
trafficking and enzymatic cleavage of secreted peptides from prohormone
precursors.

A renaissance of scientific interest in POMC has occurred in

more recent years with the cloning of a gene family of melanocortin
receptors and the demonstration of central melanocortin effects on energy
homeostasis.

This chapter will review the ongoing role that spontaneous and

induced (transgenic and "knockout") mutant mouse models have played in
the analysis of POMC gene regulation and biological function.
Biosynthesis and Post-translational Processing of POMC
Several comprehensive reviews of POMC processing have been published (3,
4). This section will serve only to introduce major points relevant to the mouse
models under consideration and is summarized in Table

1. The principal sites
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of POMC expression are corticotrophs and melanotrophs of the pituitary gland
and subsets of neurons in the arcuate nucleus (ARC) of the hypothalamus and
in the caudal nucleus of the solitary tract (NTS) within the dorsal vagal
complex of the medulla (5-7). Endoproteolytic cleavage of POMC by a
prohormone convertase (PC1/PC3) in corticotrophs yields ACTH, l3LPH, and
an NHrterminal peptide (Pro-yMSH). The latter peptide and/or further
proteolytic derivatives have been postulated to mediate paracrine growth and
secretory effects within the anterior lobe and to stimulate mitogenesis in the
adrenal cortex (8, 9). A small proportion of !3LPH is cleaved to yield yLPH
and (3ENDI-31. However, in melanotrophs of the intermediate lobe virtually
all l3LPH is cleaved by PC2 to yLPH and (3ENDI-31. The latter peptide is
acetylated on its NH2-tyrosine and truncated by the action of a
carboxypeptidase to yield Ac-13ENDI-27 and Ac-13ENDI-26. The acetylated
opioid peptides have a greatly reduced affinity for ll and 8 opioid receptors
and their biological function has not been satisfactorily determined. aMSH is
acetylated on its NH2-serine and amidated on its COOH-terminal to yield a
fully bioactive peptide. BMSH is an additional endoproteolytic product of
human yLPH but is not generated from rodent yLPH because it lacks the
necessary consensus amino acid sequence for cleavage by a PC.
Endoproteolytic processing of POMC in ARC neurons closely mirrors the
processing in melanotrophs. The neuronal aMSH is fully amidated, but there
is minimal NH2.acetylation of peptides or COOH-terminal shortening of
13ENDI-31. yMSH and/or y3MSH are processed from the NHrPOMC domain
in ARC.
Table 1.

POMC Peptides and their Cognate G-Protein Coupled Receptors
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Five distinct members of a G-protein coupled, melanocortin receptor gene
family have been cloned (reviewed in (I 0)). MC1-R is expressed on
melanocytes within the skin and its activation by Ac-aMSH-NH2 leads to
increased membrane adenylyl cyclase activity by interaction with Gsa and
subsequently greater production of the brown-black eumelanin pigment and
less of the yellow-red phaeomelanin. MC2-R is the classical ACTH receptor
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expressed on zona glomerulosa and fasiculata cells of the adrenal cortex and
it has very low affinity for the various melanocortin peptides other than
ACTH and ACTHI-24 (11). Two additional members of the gene family,
MC3-R and MC4-R are expressed exclusively in the CNS in partially
overlapping but distinct neuroanatomical areas with particularly high
abundance in the hypothalamus and limbic system (12, 13). The MC3-R has
the highest affinity for yMSH, although it is also activated by other
melanocortins, while the MC4-R is activated most selectively by aMSH and
ACTH. Together these receptor subtypes mediate most of the described
melanocortin effects on appetite, metabolism, thermoregulation, autonomic
outflow, and behavior. The MC5-R is the most ubiquitously expressed of the
melanocortin receptors and its best-documented function is the stimulation of
exocrine function including the sebaceous, preputial, Harderian, and lacrimal
glands (14).
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Three opioid receptor genes have been cloned corresponding to the f.!, &, and
receptors originally defined by their pharmacological profiles (15, 16).
PENDl-31 has highest and nearly equivalent affinity to both f.! and &
receptors (17). However, each of these subtypes has significant affinity for
other opioid peptides derived from the proenkephalin and prodynorphin
precursors.
K

POMC Peptides and Energy Homeostasis

Classical ablation or disconnection experiments utilizing electrolytic and
chemically generated lesions or knife cuts of the mammalian brain revealed a
number of discrete areas within the medial-basal hypothalamus to be nodal
points in the regulation of energy homeostasis (reviewed in (18)). One
principal area characterized in this fashion is the ARC located at the base of
the hypothalamus and adjacent to the third ventricle. The ARC extends
rostrocaudally from the posterior border of the optic chiasm to the anterior
border of the mammillary nuclei. A subset of hypothalamic neurons
distributed throughout the ARC express the POMC gene. These POMC
neurons densely innervate other brain areas implicated in energy
homeostasis, motivated behavior, and autonomic control including the
vetromedial nucleus of the hypothalamus (VMN), dorsomedial nucleus of the
hypothalamus (DMH), paraventricular nucleus of the hypothalamus (PVN),
lateral hypothalamic area (LH), ventral tegmental area (VTA), parabrachial
nucleus, and NTS.
The lesion studies showed that disruption of the mammalian ARC correlated
with an obese phenotype and led to the concept that this area of the
hypothalamus contained a satiety center. Later efforts focused on
determining the specific neuronal phenotype in the ARC that was involved in
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the regulation of energy homeostasis. An early indication of the importance
of POMC peptides was the detection of MSH binding by autoradiography in
the VMN, another hypothalamic nucleus involved in regulating appetite and
feeding (19). In addition, central or peripheral injections of melanocortin
peptides were shown to affect food intake. Melanocortins appear to have
dual roles in energy balance, depending on the site of action. Administration
of ACTH and Ac-aMSH directly into adipose tissue increases lipolysis
whereas intramuscular injection of DesAc-a.MSH increases food intake.
Furthermore, peripheral DesAc-a-MSH inhibits pituitary production of ACTH
and Ac-a.MSH, which may lead to increased lipogenesis (20). MSH
analogues administered i.c.v. or injected stereotaxically directly into the PVN
of rodents have potent anorexigenic effects and stimulate metabolic rate (21).
Exogenous opiates and endogenous opioid peptides have also been shown to
affect food consumption and food preference, suggesting a role for POMC
derived f3-endorphin, in addition to the melanocortin peptides, as a modulator
of energy homeostasis (22-24). The physiology of this complex
neuroendocrine system is virtually impossible to replicate in in vitro models.
Thus, transgenic mice and mice with naturally occurring mutants or targeted
genetic alterations have been extremely informative tools for the analysis of
POMC peptides and their receptors in the control of food intake, energy
partitioning, and body weight.
One of the first mutant mouse models of obesity to be studied was the lethal
yellow (Aria) mouse (25). The mutation arose spontaneously in the C57BL/6
inbred strain and is associated with a striking yellow coat color and the
development of obesity and hyperphagia. Genetically, the mutation was
shown to be dominant to the extension (E) locus, later identified as the gene
encoding the MC-1 receptor (26). Cloning of the agouti gene revealed that it
encodes a secreted protein characterized by multiple pairs of intrachain
disulfide bonds in its C-terminal domain. Agouti has high affinity binding for
the MC1-R, antagonizes receptor activation by MSH (27), and is normally
transiently expressed only in the hair follicles accounting for the yellow
banding of individual black hairs in the fur of many mammals. The mutant
Ar allele results from a 120 kb genomic deletion and juxtaposition of the
agouti coding sequences to the Raly gene locus and subsequent ubiquitous
expression of agouti protein from the Raly promoter (25). These observations
led to the agouti-obesity hypothesis, which states that agouti protein
expressed within the brain antagonizes the action of central MSH to a neural
MC receptor involved in regulation of energy balance. Some of the
experimental models reviewed in this chapter provide essential data in
support of this hypothesis, which has been further validated by the discovery
and cloning of an agouti homologue, agouti gene-related protein (AGRP).
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Genetic linkage studies and quantitative trait loci analyses have strongly
implicated the POMC gene locus as an important determinant of weight
homeostasis in humans of many different ethnic populations, although
specific alleles associated with obesity have not yet been demonstrated (29,
30). Because no mutations within the coding region of the POMC gene that
alter peptide activity have been identified in these populations, a current
hypothesis is that mutations in regulatory regions of the gene decrease the
level of POMC expression in the brain. However, a small number of
children from cosanguineous parents have been found to have null mutations
in the POMC gene resulting in the absence of detectable circulating ACTH
(31). These children presented with a syndrome of red hair, adrenal
insufficiency and severe, early-onset obesity. In addition, both dominant and
recessive mutations in the MC4-R gene have been found in the human
population, and MC4-R mutations have been proposed to play a role in as
many as 5% of pediatric obesity cases (32, 33).
POMC GENE REGULATION

A standard method to characterize the cis DNA elements and transcription
factors that control POMC gene transcription has been the expression of
fusion genes, consisting of POMC promoter sequences and a reporter
sequence, in transfected cell lines. The most commonly used cell line is
AtT20, originally derived from a radiation-induced pituitary tumor (34).
These cells have many characteristics of primary corticotrophs. Snrtall cell
lung cancers often ectopically express POMC and cell lines derived from
these tumors have also been used for the analysis of POMC gene expression
(35). It is clear, however, that neither of these cell lines are adequate models
for elucidation of the mechanisms governing neural-specific expression of
the POMC gene. For this reason, our laboratory has focused on a transgenic
mouse approach for the identification of cell-type specific regulatory
elements in the POMC gene.
Promoter Analysis in Transgenic Mice

The Drouin laboratory was the first to report the generation of transgenic
mice expressing a neomycin-resistance coding sequence (neo) from 770
bases of the rat POMC promoter (36). Although the expression pattern in
pituitary and regulation by adrenalectomy and dexamethasone were
consistent with accurate cellular expression of the transgene, the low levels
of transcript from the neo reporter prevented the direct demonstratation of
corticotroph and melanotroph specific transcription. Our laboratory initially
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approached this problem using an E. coli lacZ reporter gene encoding a
galactosidase, which was useful for both the precise cellular identification of
transgene expression and quantitation of transcriptional activity by an
enzymatic assay utilizing a fluorigenic substrate. These studies demonstrated
that 770 bases of the rat POMC promoter from nucleotide -706 in the 5'
flanking sequences to +64 in the 5' untranslated region of exon 1 were
sufficient to direct lacZ expression selectively to pituitary corticotrophs and
melanotrophs (Figure 1, POMC-LacZ) (37). The ontogeny of transgene
expression also closely approximated the time course of endogenous POMC
gene expression in the two lobes of the pituitary gland. However, there was
no detectable expression of the -706POMC-lacZ transgene in the brain
suggesting that additional genomic sequences were necessary for neuronal
transcription.
Additional studies from our laboratory analyzed the rat POMC promoter in
more detail to define the minimal elements essential for pituitary expression
(38, 39). Accurate cell-specific colocalization was verified in all instances by
double-label immunofluoresence histochemistry. Truncations of the rat
POMC promoter to nucleotide -323 or -234 had minimal effects on both the
ratio of expression-positive to total transgenic pedigrees and qualitative
levels of reporter expression in the positively expressing lines. Further
deletion of the 5' flanking sequences to nucleotide -160 abolished expression
in the pituitary gland. Transfection studies in AtT20 cells had identified
important regulatory elements in the core promoter region of the POMC
gene. However, we demonstrated that the enhancerless promoter and TATA
box from the HSV1 thymidine kinase gene were equivalent to the native
POMC promoter sequences between nucleotides -34 and +64, in the context
of upstream flanking sequences of POMC, to support pituitary cell-specific
expression and normal upregulation by adrenalectomy. Based on these
promoter truncation studies in transgenics and our data from DNAse I
protection assays and gel-shift assays utilizing POMC oligonucleotide probes
and fractionated nuclear proteins from AtT20 cells, we designed a series of
more discrete mutations in the rat POMC promoter. This second generation
of transgenic experiments identified two functionally important protein
binding sites at nucleotide positions -262/-253 and -202/-193 of the POMC
gene (39). At least one of these sites had to be intact to support detectable
pituitary expression of the transgenes. In addition, the ubiquitous
transcription factor SP1 appeared to play a supportive role in POMC
transgene expression through its interaction with DNA sites at positions
-201/-192 and -146/-136.
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Fig 1. Restriction maps of the mouse POMC gene locus, transgene
constructs utilized to map the location of tissue-specific regulatory elements,
and targeted POMC alleles that either selectively prevent B-endorphin
production or result in the absence of all POMC peptides. See text for details
of the individual alleles.

None of the transgene constructs that we studied selectively directed
expression to only pituitary melanotrophs or corticotrophs, suggesting that
both cell types share one or more essential components for POMC gene
transcription. In common with most published transgenic promoter analyses,
we observed a large quantitative and qualitative range of expression levels
among independent pedigrees for each construct. It has been suggested that
these mosaic patterns of gene expression are influenced by repressive effects
of multiple-copy transgene integration in some cases (40). In general, basal
expression of the transgenes appeared to be greater in individual
melanotrophs than corticotrophs, regardless of the type of reporter molecule.
The data from our transgenic promoter analyses revealed a number of
inconsistencies with the mapping of functional POMC promoter elements by
transfection studies in AtT20 cells. These differences may be due in part to
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the more stringent requirement in transgenic mice for the definition of cell
specific expression and the importance of chromatin remodeling during in
vivo development. However, there is good agreement between both kinds of
studies for the key importance of DNA elements between nucleotides -I60
and -323 in the 5' flanking domain of the POMC gene. This region contains
a site between -I73/-I60 that appears to mediate the transcriptional activating
effects of both corticotroph releasing hormone (CRH) and the cytokine
leukemia inhibitory factor (LIF), although it is neither a binding site for
CREB, AP-I or STAT proteins (4I). In contrast, the POMC TATA box, a
putative AP-I binding site in exon I, and more distal sites in the POMC 5'
flanking sequences that bind HLH proteins and confer a synergistic
activation of POMC expression in AtT20 cells do not appear to be essential
for pituitary cell-specific expression in the in vivo paradigm (42).
Generation of Novel POMC Expressing Cell Lines

1,,,

Targeted cellular expression of oncogenes with tissue-specific promoters has
led to new insights into the molecular basis of tumorigenesis. Several
laboratories have used this technique to isolate novel differentiated cell lines
(43-46). We used the rat POMC promoter elements to express two isoforms
of the simian virus SV40-Large T antigen in pituitary corticotrophs and
melanotrophs. Wild-type SV40Tag consistently induced tumors in the
pituitary gland, as predicted, but also in the thymus gland with incomplete
penetrance of the phenotype (47). However, the incidence of thymic tumors
decreased and eventually disappeared after I5 generations of backcrossing to
an outbred CD-I genetic background, suggesting that epistatic interactions
with gene alleles from the original B6D2 genetic background were necessary
for expression of the transgene in thymus. In contrast, the pituitary tumor
phenotype remained stable after 27 generations of breeding (48). The
variable latency to tumor development in these mice is consistent with the
idea that stochastic secondary events likely occur in individual T-antigen
expressing cells before they are transformed and lose their inhibitory growth
controls. Other transgenic mice expressing the temperature-sensitive tsA58
mutant form of SV40Tag from the same POMC promoter sequences only
developed pituitary tumors after I year of age (our unpublished data). The
longer latency was presumably due to the expression of minimal amounts of
biologically stable tsA58-Tag at the partially permissive core body
temperature of the mice.
Although the POMC-Tag transgene is expressed in both pttmtary
corticotrophs and melanotrophs, every pituitary tumor that has developed in
the mice has been of melanotroph origin based on visual inspection and
biochemical and molecular studies. The melanotroph tumor cells are fully
transformed because they will produce secondary tumors after subcutaneous
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passage in nude mice and will freely grow in suspension culture (47, 49).
Unlike the strict dependence for IGF-II in the induction and progression of
pancreatic islet J3-cell tumors from an insulin promoter-Tag transgene (50),
we found no evidence for a critical role of the IGF system in the POMC-Tag
induced pituitary tumors (51). Posttranslational processing of POMC in the
primary tumors was indistinguishable from normal melanotrophs and was
characterized by high proportions of NH2-acetylated and COOH-truncated
forms of J3-endorphin and Ac-aMSH with virtually no ACTH (47). Even
though the tumors expressed high levels of PC2, which is characteristic of
melanotrophs, there was frequently a sufficient quantity of an ACTH-like
peptide secreted from the neoplastic glands to induce adrenal cortical
hyperplasia and elevated serum corticosterone. A syndrome of fatal
melanotroph-dependent Cushing's disease was recently reported in mice with
a null mutation in the gene encoding the neuroendocrine protein 7B2 (52)
(see Chapter 8). 7B2 has been implicated in the activation of PC2, accounting
for the lack of functional PC2 production and generation of ACTH instead of
Ac-aMSH and CLIP in melanotrophs of the 7B2 null mice. However, it
remains unexplained why ACTH is constitutively secreted from the
intermediate lobe of these mice because a knockout of the PC2 gene results
in similarly high ACTH production in melanotrophs without the unregulated
secretion of the hormone (53). Therefore, 7B2 may have an additional
function in vesicular trafficking or secretion.
Two cell lines with distinct phenotypes were isolated from cultures of the
mouse melanotroph tumors (54). miL39 cells are melanotrophs based on
their expression of both POMC and the dopamine 02 receptor. They are
small, bipolar cells and rapidly produce secondary tumors after
transplantation into nude mice. In contrast, miL5 cells fail to express either
POMC or detectable levels of SV40Tag. The exact origin of these latter cells
is unknown but they are of interest because they secrete a prolactin
regulating factor. The lack of concordance between this prolactin-regulating
.·ctivity and POMC gene expression suggests that the activity is not due to a
peptide product of POMC. More recently our laboratory has isolated another
melanotroph-like cell line from a pituitary tumor induced by the
tsA58SV40Tag (Chronwall et al, submitted). These cells express high levels
of POMC mRNA and POMC prohormone but they have few secretory
granules and limited posttranslational processing of POMC. Preliminary
studies have demonstrated the expression of several G-protein coupled
receptors including dopamine 02, CRH Rl, and GABAB that are normally
expressed on melanotrophs. These receptors are functional and therefore this
cell line may be useful for analyzing the biochemical cross-talk in signaling
pathways that are unique to pituitary melanotrophs.
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Targeting POMC Neurons In Vivo

Because neither 770 or 4000 bp of the 5' flanking sequence from the rat
POMC gene were sufficent to produce appropriate neuronal expression in
transgenic mice (55), longer mouse genomic POMC clones were isolated
from a cosmid library. Exon 3 was marked with an oligonucleotide sequence
to distinguish transgenic mRNA from endogenous POMC mRNA and to
enable the simultaneous quantitation of both mRNA species by an RNAse
protection assay. A new series of transgenic mice was generated and analyses
of mRNA expression in the mice clearly established the location of a putative
neuron-specific enhancer within an 11 kb stretch of 5' flanking DNA
sequences between -13 kb and -2 kb relative to the transcriptional start site
(Figure 1, L\3'P27* and HAL*) (56). Transgene constructs containing these
sequences have had a 100% penetrance of correctly targeted expression in
neurons of both the ARC and NTS, consistent with the existence of a locus
control type regulatory element within the POMC gene. There is also total
concordance of pituitary expression with neural expression from the longer
genomic constructs indicating that an overlapping subset of POMC
regulatory elements and cognate transcription factors may be required for
transcription in both cell types. The recent identification of a novel
neuropeptide precursor gene, cocaine and amphetamine responsive-transcript
(CART), as a cotransmitter in POMC arcuate neurons suggests that these two
distinct genes may also share a subset of regulatory factors (57, 58).
Ongoing functional analyses of the distal POMC genomic sequences
combined with recent advances in the human and mouse genome projects
should rapidly lead to the identification of the minimal DNA elements that
are responsible for neural-specific expression. It will then be possible to
compare these sequences with the corresponding regions of DNA amplified
from obese subjects to test the hypothesis that mutations in POMC regulatory
sites are the molecular basis for the genetic linkage established by QTL
analyses (29). Ultimately, the functional significance of nucleotide
differences identified by this type of horizontal genetic comparison can be
tested in mice by targeted mutagenesis and analyses of POMC expression in
hypothalamus, feeding behavior, and energy partitioning.
Our characterization of neural-specific regulatory regions in the POMC gene
provided a means to identify viable POMC neurons using a nondestructive,
green fluorescent protein (enhanced-GFP) reporter (Cowley et al.,
submitted). Previously, the analysis of cellular events in POMC neurons has
been limited because of their small number and sparse distribution. Bright
green fluorescence was readily identified in the basal hypothalamus and in
the NTS of transgenic mice expressing a POMC-EGFP construct (Figure 1).
Double-labeling immunofluorescence with a B-endorphin antisera revealed
>99% cellular colocalization of EGFP and endogenous POMC peptide
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expression within the ARC. The developmental onset of EGFP expression in
both hypothalamic and pituitary cells also matched the ontogeny of native
POMC.
POMC neurons are an important site of leptin receptor expression in the
hypothalamus (59). The adipocyte derived hormone leptin regulates long
term aspects of energy homeostasis by signaling the levels of fat mass to the
brain. Leptin also has acute actions to stimulate cjos and Socs3 expression
in POMC neurons and can cause the release of B-endorphin from
hypothalamic fragments in vitro (60). Therefore, the POMC-EGFP
transgenic mice will be a useful tool to test the hypothesis that leptin directly
activates POMC neurons. Preliminary electrophysiological experiments in
hypothalamic slices suggest that leptin has both pre- and postsynaptic actions
on POMC neurons to increase the frequency of spontaneous action
potentials. Additional studies using this transgenic mouse line will decipher
the role of other peptidergic modulators, cytokines, and amino acid
neurotransmitters on POMC neuronal activity. EGFP-labeled POMC neurons
can also be used for investigation of neuronal migration during development
and as a unique source of mRNA for differential gene expression analyses.
Similar techniques to identify rare neuronal populations in vivo are
increasingly being used by other laboratories. A prime example is the
identification of GnRH neurons as described in Chapter 3 of this volume and
by other investigators (61).
In principle, the neural-specific regulatory sequences of the POMC gene can
be used to target expression of foreign or mutated proteins to POMC neurons
to investigate intracellular signaling pathways in situ. For example, leptin
resistance may be associated with alterations in the capacity for leptin
signaling through either JAK/Stat or MAPK cascades. Individual molecular
steps in these pathways could be perturbed by the use of dominant-negative
factors or expression of natural inhibitor proteins. Finally, targeted oncogene
expression to POMC neurons may lead to the isolation of a differentiated
POMC neuronal cell line, which would greatly facilitate molecular studies of
POMC gene regulation and the membrane properties of the neurons
themselves.
MUTATIONAL ANALYSIS OF POMC FUNCTION
TARGETED MUTAGENESIS OF THE POMC GENE
13-endorphin-Deficient Mice

B-endorphin-deficient mice were generated by the introduction of a point
mutation into the POMC gene by homologous recombination in embryonic
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stem cells (62). The nucleotide insertion at the amino-terminal tyrosine of
BEND introduced a premature translational stop-codon into exon 3 (Figure 1,
construct POMCX*4). Homozygous mice carrying this mutated allele
express normal levels of POMC mRNA in pituitary and ARC. The mRNA
encodes a COOH-truncated POMC prohormone that is processed normally to
ACTH and other melanocortin peptides (63). The mice have no detectable
immunoreactive BEND and have been used to infer the normal physiological
function of this specific endogenous opioid peptide. Basal activity of the
hypothalamic-pituitary-adrenal axis is normal and the PEND-deficient mice
have normal corticosterone responses to a variety of stressors. PEND
deficient mice exhibit unaltered nociceptive thresholds and unaltered
antinociceptive responses to i.p. morphine administration. However, PEND
deficient mice fail to exhibit endogenous opioid-mediated stress-induced
antinociception and have increased levels of nonopioid (naloxone insensitive)
stress-induced antinociception (63). Complimentary studies in enkephalin
deficient mice have demonstrated that they retain endogenous opioid stress
induced antinociception (64). Taken together, these data provide convincing
genetic evidence that BEND derived from the POMC prohormone, and not
the more abundant enkephalin peptides, is the natural opioid mediating
stress-induced antinociception. The most likely relevant neuroanatomical
substrate is the projection of ARC POMC neurons to the central
periaqueductal gray known to modulate descending antinociceptive pathways
to the brainstem and spinal cord.
More recent studies have demonstrated that the BEND-deficient mice have
altered antinociceptive responses to morphine administered i.c.v. or i.t. The
mutant mice are more sensitive to the antinociceptive action of morphine
injected centrally into the lateral ventricle but less sensitive to morphine
injected into the spinal compartment, compared to wild-type control mice
(65). The f..l-Specific agonist DAMGO produced qualitatively identical results
indicating the importance of the fl opioid receptor in the phenotype. Total
binding sites for the fl, 8, and K receptors, assessed by quantitative
autoradiography, were normal in the BEND-deficient mice suggesting that
subtle alterations in fl receptor signaling may be the mechanism for the
opposing alterations in central and spinal sensitivity to morphine. An
electrophysiological study demonstrated a normal dose-response to DAMGO
for the induction of an inwardly rectifying K+ current (GIRK) in mediobasal
hypothalamic neurons of the mutant mice (66) consistent with the suggestion
that fl receptor number, affinity, and coupling to G proteins are not altered by
the complete absence of BEND.
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Opioids, including PEND, have generally been shown to increase food intake
in pharmacological studies (67). Paradoxically, p-endorphin deficient mice
exhibit a sexually dimorphic obesity phenotype due to increased white fat
mass in males (Appleyard et al, submitted). The male mice are slightly
hyperphagic and have a normal basal metabolic rate. It is not yet clear if
POMC derived melanocortins and 13END are involved in a parallel,
redundant anorexigenic pathway within the hypothalamus or if PEND
additionally plays a role in an opioid reward pathway that is activated by
feeding.
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Null Mutation of the POMC Gene

Mice that are deficient in all POMC peptides (POMC Null) were generated
by the Hochgeschwender laboratory by homologous recombination of a
POMC allele containing a deletion of exon 3 (Figure 1, POMC Null). The
mice develop hyperphagia and obesity similar to that seen in the lethal
yellow (Aria) mice and MC4-R deficient mice (68). In contrast to the other
obesity models, POMC Null mice have no detectable levels of circulating
corticosterone or epinephrine and their adrenal glands are one-third the size
of wildtype littermates. The adrenal deficiencies in these mice strengthen the
hypothesis that normal POMC expression is needed for complete adrenal
maturation, although the role of NH2-terminal peptides in addition to ACTH
remains an open question that can now be approached experimentally in vivo.
A partial perinatal lethality occurs in litters produced from heterozygous
breeder pairs leading to significantly decreased numbers of homozygous
POMC Null offspring compared to Mendelian predictions. Homozygous
POMC Null adults are fertile and females carry their litters to term but all
pups die in the immediate perinatal period (our unpublished data). The
mechanism for this pattern of perinatal lethality from both heterozygous and
homozygous POMC Null female mice has not yet been explained, but may
result from the combined lack of glucocorticoids and epinephrine in the
POMC Null pups.
In principle, the absence of all POMC peptides should recapitulate the sum of
phenotypes observed in mice deficient in the various receptor subtypes for
the peptides. Although not all the characteristics of the various receptor
deficient mice have been investigated, some of the predicted phenotypes are
absent in the POMC Null mice. In particular, POMC Null mice do not
exhibit the hair pigmentation that would be expected based on the
phenotypes of Ar ia yellow and null MC1-R mutants (see discussion in the
following section). The original POMC Null mice bred on an agouti (AlA)
129 genetic background had patchy alterations in their coat color, but were
clearly not a uniform yellow (68). We have crossed the POMC Null allele
onto the C57BL/6 (ala) genetic background and observed an unaltered black
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Tran.

coat color in the mutant mice despite the absence of MSH, the only known
natural agonist for the MCI-R (unpublished data). In sum, POMC deficient
mice will be invaluable in deciphering the physiological roles of individual
POMC peptides in the neuroendocrine and immune systems by transgenic
strategies designed to rescue the expression of subsets of POMC products to
either the pituitary and/or neural compartments.

lTilce
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MELANOCORTIN AND OPIOID RECEPTOR GENE MUTATIONS
Hypomorphic and Constitutively Active MCl-R Gene Alleles

.: I

Classical genetic studies indicated that two independent loci, extension (E)
and agouti (A), primarily controlled the ratio of eumelanin and phaeomelanin
in melanocytes, and hence the color of individual hairs. The extension locus
is cell-autonomous and approximately a decade ago was demonstrated to
encode the MCR-1 or MSH receptor (26). Numerous naturally occuring
mutations at the extension locus have been characterized genetically because
of the relative ease in tracing the mutant alleles during backcrosses and
intercrosses by observation of coat color. Recessive mutations of the mouse
extension locus (e) result in a yellow coat color due to low levels of
tyrosinase activity in melanocytes and a high phaeomelanin/eumelanin
pigment ratio. The e allele encodes a nonfunctional MCR-1 resulting from a
frameshift mutation and premature translational stop codon between the
fourth and fifth transmembrane domains. Dominant mutations of the mouse
E locus result in black coat color and are epistatic to agouti. The sombre (E')
allele encodes a MCI-R containing a single activating point mutation. This
MCI-R is constitutively active in the absence of MSH and therefore not
antagonized by agouti protein, accounting for the genetic epistasis. These
original data and the analyses of other mutant E alleles have been the basis of
structure-function models to explain receptor activation by agonist ligand
binding. Interestingly, identical mutations introduced into the other highly
homologous MCR subtypes have generally not resulted in receptor activation
emphasizing the important functional differences among these related G
protein coupled receptors and the danger of over extrapolating data
concerning ligand interactions from one receptor subtype to another.
Null Mutation of the MC4-R Gene

Targeted deletion of the MC4-R has shown it to play an important role in
energy homeostasis. MC4-R is the predominant melanocortin receptor in the
brain and genetically engineered mice homozygous for a null MC4-R allele
an� obese, hyperphagic, and exhibit increased longitudinal growth (69), all
features shared with the Aria yellow mouse. These data and the inability of
the potent MSH analogue MTII to decrease food intake in MC4-R knockout
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mice (70) indicate that the MC4-R is essential for the anorectic effects of
central melanocortins.
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Null Mutation of the MC5-R Gene

Transgenic mice deficient in the MC5-R do not exhibit any phenotypes that
are directly associated with weight regulation or feeding but they do exhibit
thermoregulatory defects and fail to repel water from their coat. These
phenotypes were shown to be a result of reduced production and secretion of
lipids from sebaceous glands in MC5-R deficient mice (14). Additionally, the
mice exhibited decreased production and attenuated stress-induced synthesis
of porphyrins by the Harderian glands and decreased protein secretion from
lacrimal glands. All of these exocrine glands, including the preputial gland,
are normally sites of high MC5-R expression. The results suggest the
existence of a hypothalamic-pituitary-exocrine axis that potentially regulates
pheromone production from exocrine glands in coordination with the
behavioral arousal state of the mouse.
Null Mutations of the MC3-R Gene

Null mutations of the POMC (68) and MC4-R (69) genes, and transgenic
overexpression or misexpression of the MC4-R antagonists agouti and AGRP
(28, 71) all produce phenotypes that can be attributed to diminshed MC4-R
signaling. Although these genetic models have provided great insight into the
role of POMC and MC4-R in energy homeostasis, little specific information
can be extracted regarding a contributory role of MC3-R signaling. The
MC3-R, like the MC4-R, is expressed in the CNS but in a more restricted
distribution including ARC and VMN. Recently, two groups independently
published reports of knockout mice lacking the MC3-R (72, 73). MC3-R
deficient mice exhibit nearly normal growth curves and body weight, but
carcass analyses reveal a significant increase in white adipose mass.
Additionally, MC3-R deficient mice are more susceptible than controls to
developing obesity on a high fat diet. In contrast to the obesity phenotype
exhibited in MC4-R deficient mice, which can mostly be explained by
alterations in feeding behavior, the MC3-R deficient mice apparently have a
predominant metabolic defect involving energy partitioning. They have
higher feed efficiency and decreased lean mass. Mice lacking both the MC3R and MC4-R gain more weight than single MC4-R knockouts (73).
Additional studies are needed to define the specific neural circuits
responsible for the divergent actions of melanocortin peptides, MC3-R, and
MC4-R on the regulation of food intake versus metabolic rate and energy
expenditure.
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Null Mutations of the Opioid Receptor Genes
Each of the three genes encoding the classical opioid receptor subtypes has
been deleted by homologous recombination in mice (16). Surprisingly, there
have been no published reports regarding the effects of these mutations on
food intake and energy homeostasis. Based on our findings in the BEND

deficient mice, we would predict that f..l receptor knockout mice are the most

likely to have a phenotype relevant to the physiologic regulation of body
weight and fat mass.
SUMMARY AND FUTURE PROSPECTS
Complex interactions between the nervous system and the endocrine system
are essential for the regulation of energy homeostasis. Transgenic and
targeted

gene mutational

studies have

demonstrated that neuropeptides

derived from the POMC prohormone and their cognate G-protein coupled
receptors are key elements of communication between and within these two
important biological systems. Transgenic models have identified POMC
neurons in the ARC as a prominent component of the hypothalamic neural
circuitry that modulates energy homeostasis. Moreover, melanocortin and
opioid peptides derived from POMC may have both additive and opposing
actions in the balance of caloric intake and expenditure. Many of the
mutations described in this chapter give rise to multisystem physiological
disturbances and could also involve undetected developmental alterations,
therefore one must be circumspect in the assignment of a specific peptide or
receptor subtype as the major determinant in a disease. As a result, newer and
more

sophisticated molecular and genetic approaches to

in vivo

gene

mutations, such as conditional gene deletion and regulation, are currently
being

explored.

characterization

These
of

newer

specific

techniques

will

endocrine-disease

permit

a

more

pathophysiology,

detailed
and

in

addition, help to reveal the function of each biologically active POMC
peptide

in vivo.
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